What is Lantheus Holdings's latest dividend and current dividend yield?

What guidance did Lantheus Holdings's management provide for the next earnings period?

What is the market's earnings forecast for Lantheus Holdings next quarter?

What does Lantheus Holdings do and what are its main business segments?

What is Lantheus Holdings's gross profit margin?

What factors drove the changes in Lantheus Holdings's revenue and profit?

Did Lantheus Holdings beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Lantheus Holdings year over year?

- **Strategic Shift to Diagnostics**: Divested SPECT business, prioritizing PET radiodiagnostics like Neuraceq (+100%+ 2026 growth) and OCTEVY (FDA March 29). 
- **PSMA Franchise Resilience**: PYLARIFY volume growth offset 8-10% net revenue decline; new PSMA PET formulation targets Q4 2026 launch with TPT reimbursement.
- **Financial Guidance**: 2026 EPS $5-5.25, revenue $1.4-1.45B. Neuraceq and DEFINITY drive mid-term growth; R&D investment in GRPR-targeted PET.
- **Pipeline Optimization**: PNT2003 launch planned; exploring external partnerships for non-core therapeutics.

**【CEO Summary Section】**
- **Strategic Pivot to Diagnostics**: Focused on PET radiodiagnostics, divested legacy SPECT business, and prioritized pipeline assets like Neuraceq (beta-amyloid PET) and OCTEVY (gallium-based NET imaging).
- **Portfolio Expansion**: Acquired Neuraceq in 2025, expecting >100% growth in 2026; OCTEVY PDUFA date March 29, 2026. Advanced Lantheus 2401 (GRPR-targeted PET) to Phase III.
- **PSMA Leadership**: Maintained PYLARIFY volume growth despite 8-10% net revenue decline; new PSMA PET formulation PDUFA March 6, 2026, targeting seamless PMF rollout in Q4 2026.
- **Pipeline Optimization**: Evaluating therapeutic assets for external partnerships; PNT2003 (radioequivalent Lutathera) awaiting FDA approval.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Revenue $406.8M (+4% YoY), PYLARIFY $240.2M (-9.7% YoY), Neuraceq $31M (new acquisition). Adjusted EPS $1.67 (+4.7% YoY).
- **2026 Outlook**: Revenue $1.4-1.45B, EPS $5-5.25. PYLARIFY net revenue down 8-10% YoY; Neuraceq >100% growth, DEFINITY low-single-digit growth.
- **Margins & Expenses**: Gross margin ~65.5%, R&D 10-11% of revenue, G&A flat at 10% of revenue. Free cash flow $81.4M Q4 2025, $359.1M cash on hand.

**【Q&A Highlights】**
- **PSMA PET Transition**: New formulation PDUFA March 6; HCPCS code and TPT status expected by October 1, 2026. Regional PMF rollout to minimize disruption.
- **Competitive Dynamics**: PYLARIFY pricing disciplined; competitor losing TPT in Q3 2026 may drive share shifts. Neuraceq growth driven by PMF expansion and guideline adoption.
- **Therapeutic Pipeline**: PNT2003 launch aligned with nuclear medicine network; MK-6240 (tau PET) used in 17 pharma trials. Exploring external options for non-core therapeutics.
- **CEO Search**: Progressing with strong candidate slate; interim CEO role focused on strategic continuity.


Lantheus Holdings, Inc. (LNTH) Q4 2025 Earnings Call Transcript

- **Leadership Transition**: Brian Markison retiring, Mary Anne Heino as interim CEO, with comprehensive CEO search underway.
- **Financial Performance**: Q3 2025 revenue $384M (+1.4% YoY), adjusted EPS $1.27, with narrowed full-year guidance of $1.49B-$1.51B revenue and $5.50-$5.65 EPS.
- **Strategic Growth**: PYLARIFY volumes up 3.3% YoY, Neuraceq +25%, DEFINITY +6.3%.
- **Pipeline Momentum**: New F-18 PSMA PET formulation expected in 2026 with 3-year pass-through status.
- **Key Risks**: Pricing resets, Medicare reimbursement transition, and leadership transition execution.

**【CEO Summary Section】**
- **Leadership Transition**: Brian Markison will retire at year-end, with Mary Anne Heino serving as interim CEO. A comprehensive CEO search is underway.
- **Strategic Acquisitions**: Integrations of Life Molecular Imaging and Evergreen Therapeutics enhance radiopharmaceutical capabilities.
- **Product Performance**: 
  - PYLARIFY sales stabilized at $240.6M, with U.S. volumes up 3.3% YoY.
  - Neuraceq sales grew 25%, driven by expanded geographic coverage.
  - DEFINITY sales increased 6.3%.
- **Pipeline Advancements**: New F-18 PSMA PET formulation expected in 2026 with 3-year pass-through status.

**【CFO Financial Commentary】**
- **Q3 2025 Results**: 
  - Revenue: $384M (+1.4% YoY)
  - Adjusted EPS: $1.27 (-25.3% YoY)
  - Gross Margin: 53.5% (down 471bps YoY)
  - Operating Expenses: 32.4% of revenue
- **Full Year Guidance**: 
  - Revenue: $1.49B-$1.51B
  - Adjusted EPS: $5.50-$5.65

**【Q&A Highlights】**
- **Market Dynamics**: PYLARIFY pricing stabilization reflects disciplined execution and clinical differentiation.
- **Competitive Position**: Neuraceq growth (+25% Q3) driven by expanded PMF network and Life Molecular Imaging integration.
- ** Medicare Reimbursement**: Transitioning to MUC from ASP, with potential ASP return in 2027.
- **Risks**: Pricing resets in Q4 and 2026, leadership transition execution.


Lantheus Holdings, Inc. (LNTH) Q3 2025 Earnings Call Transcript

- **Challenges in PYLARIFY**: 8.3% YoY sales decline due to pricing competition, but volumes grew 2% YoY. New formulation with 50% larger batches expected in late 2026.
- **Diversification efforts**: Acquisitions of Evergreen and LMI add $40-45 million in 2025 revenue and expand neuro portfolio. $400 million stock buyback signals confidence.
- **2026 growth potential**: Double-digit growth achievable through 4 new product launches, despite potential flat PYLARIFY sales.
- **Financial adjustments**: Full-year 2025 revenue revised down to $1.475-1.51 billion, EPS $5.50-5.70 (-20% YoY).

**【CEO Summary Section】**
- **Revenue decline and strategic adjustments**: PYLARIFY sales dropped 8.3% YoY to $251 million due to competitive pricing pressures and account losses, particularly in MUC-based reimbursement environments. Volumes grew 2% YoY and 4% sequentially, but growth was slower than the broader market.
- **New product development**: FDA accepted the NDA for a new PYLARIFY formulation with 50% larger batch sizes, expected to improve patient access and supply resilience. PDUFA date is March 6, 2026, with potential launch in late 2026.
- **Acquisition strategy**: Acquired Evergreen and Life Molecular Imaging (LMI) to diversify revenue, expand the neurology portfolio (e.g., NEURACEQ), and add CDMO capabilities. LMI's NEURACEQ is expected to contribute $40-45 million in 2025.
- **Long-term growth drivers**: Launching 4 new products by mid-2026, including MK-6240 (tau tracer) and PNT2003 (neuroendocrine tumor agent). Board authorized $400 million stock buyback program.

**【CFO Financial Commentary】**
- **Q2 2025 financials**: Total revenue $378 million (-4.1% YoY). PYLARIFY sales $250.6 million (-8.3% YoY). Precision Diagnostics revenue $115.8 million (+3.3%), driven by DEFINITY (+7.5%) and Evergreen CDMO (+$3.4 million).
- **Profitability**: Gross margin 67.6% (-80bps YoY due to pricing pressures). Operating expenses 27.2% of revenue (+227bps YoY) due to R&D investments (+$22.3 million). Adjusted net income $110.6 million (-12.8% YoY). Free cash flow $79.1 million (+$5.6 million YoY).
- **Guidance update**: Full-year 2025 revenue revised to $1.475-1.51 billion (-$85-115 million vs. prior range). PYLARIFY sales expected $940-965 million (-$15-35 million YoY). Adjusted EPS $5.50-5.70 (-$1.00-$1.20 YoY).

**【Q&A Key Highlights】**
- **2026 growth outlook**: CEO and CFO reaffirmed potential for double-digit growth through new product launches (e.g., new PYLARIFY, MK-6240) and LMI integration. However, PYLARIFY may face flat or negative growth in 2026 due to pricing dynamics.
- **New PYLARIFY formulation**: Expected to reset 340B pricing and enable 3-year TPT reimbursement. Launch timing dependent on coding and coverage, likely Q4 2026. Will completely replace current PYLARIFY formulation.
- **Competitive dynamics**: F-18 competitor aggressive pricing caused account losses, but strategic partnerships retained 80%+ of business. Gallium competitor loses TPT in Q4 2026, creating opportunity for Lantheus.
- **Neuro portfolio expansion**: NEURACEQ label expansion and MK-6240 late-stage development position Lantheus as leader in Alzheimer's diagnostics. U.S. Alzheimer's PET market estimated to grow to $2.5 billion by mid-2030s.


Lantheus (LNTH)-6 Aug 25-2025 Q2 Earnings call transcript

- **Strategic Restructuring**: SPECT divestiture to SHINE frees up $100M+ in annual gross margin, refocusing on high-growth PET modalities.
- **Pipeline Expansion**: $10M+ in new revenue from Evergreen/LMI acquisitions, with 14+ clinical assets advancing.
- **Financial Discipline**: 2025 Adjusted EPS guidance $6.60-$6.70 reflects $0.25 dilution from acquisitions, but sets stage for 2026+ double-digit growth.
- **Alzheimer’s Leadership**: $1.5B 2030 TAM with NEURACEQ and MK-6240 launches, positioning as PET imaging leader in neurodegenerative diseases.
- **Theranostic Platform**: OCTEVY/PNT2003 pair targets $3.5B PSMA PET market, with potential to expand into post-PSMA GRPR therapies.


**【CEO Strategic Overview】**
- Announced divestiture of SPECT business to SHINE Technologies, streamlining focus on PET radiodiagnostics, microbubbles, and radiotherapeutics.
- Completed acquisitions of Evergreen Theragnostics and Life Molecular Imaging (LMI), adding $10M+ in annual revenue and expanding pipeline with assets like OCTEVY and NEURACEQ.
- 2025 priorities: integrate acquisitions, finalize SPECT divestment, and advance pipeline with 14+ clinical-stage assets.

**【CFO Financial Highlights】**
- Q1 2025 Revenue: $372.8M (flat YoY), driven by PYLARIFY ($257.7M) and DEFINITY ($79.2M).
- Gross Margin: 67% (-180bps YoY) due to Strategic Partnership pricing and supply chain challenges.
- Adjusted EPS: $1.53 (down 9.5% YoY) with $98.8M free cash flow.
- Updated 2025 Guidance: Revenue $1.55B-$1.585B, Adjusted EPS $6.60-$6.70 (down $0.40-$0.50 YoY).

**【Commercial Update】**
- PYLARIFY: Q1 sales $258M (flat YoY) with 65%+ contracted volume via Strategic Partnerships.
- Alzheimer’s Market: U.S. AD Radiodiagnostics TAM projected at $1.5B by 2030, supported by NEURACEQ and MK-6240 launches.
- DEFINITY: $79M Q1 sales, maintaining #1 ultrasound contrast agent position.

**【Pipeline Progress】**
- MK-6240 (tau imaging): Met primary endpoints in Phase 3 studies, NDA submission Q3 2025.
- OCTEVY (neuroendocrine tumor imaging): Registrational-stage asset with potential theranostic pairing with PNT2003.
- LNTH-2503: First-in-class CCK2R theranostic pair entering Phase 1/2 trials.

**【Q&A Key Takeaways】**
- PYLARIFY Guidance: Flat-to-low single-digit growth for 2025 vs prior low/mid-single-digit range.
- SPECT Divestiture: Expected to close Q4 2025, unlocking ~200bps gross margin expansion.
- R&D Investment: 7.5% of revenue (up 100bps YoY) to support pipeline expansion.
- Competitive Dynamics: Smaller sites driving 20%+ PSMA PET market growth, offsetting pricing pressure.


Lantheus (LNTH)-7 May 25-2025 Q1 Earnings call transcript

- **Pylarify Breaks $1B Sales Barrier**: 2024 revenue of $1.058 billion, +24% YoY
- **Double-Decimal Growth by 2026**: Acquisitions of Life Molecular Imaging and Evergreen Therapeutics to add $1.5B+ Alzheimer's market
- **Stable Pricing Environment**: CMS MUC rule provides predictable reimbursement, ASP-based payment could accelerate growth
- **Strong Cash Flow**: $493M free cash flow in 2024, guided to $550-600M in 2025
- **Pipeline Expansion**: 2025 NDA submissions for MK-6240 Tau tracer and PNT2003 radiotherapeutic

**【CEO Summary Section】**
- Lantheus achieved record revenue of $1.534 billion in 2024, driven by Pylarify becoming the first radio diagnostic blockbuster with $1.058 billion in sales. 
- Announced two strategic acquisitions (Life Molecular Imaging and Evergreen Therapeutics) expected to close in H2 2025, adding $1.5 billion+ Alzheimer's diagnostics market and new theragnostic pairs for oncology.
- CMS rule change for radiopharmaceutical payments will support long-term growth of Pylarify and pipeline assets like MK-6240 and NAV-4694.

**【CFO Financial Commentary】**
- Q4 2024 revenue: $391.1 million (+10.5% YoY), full year: $1.534 billion (+18.3% YoY)
- Pylarify sales: $266 million (Q4) / $1.058 billion (FY24), +15.7% YoY
- DEFINITY sales: $86.2 million (Q4) / $317.8 million (FY24), +17.9% YoY
- Gross margin: 68% (Q4) / 68.3% (FY24), stable despite one-time costs
- Free cash flow: $493.1 million FY24, guided to $550-600 million FY25
- Share buybacks: $100 million Q4, $150 million remaining authorization

**【Q&A Key Highlights】**
1. **Pylarify Growth Outlook**: 
   - 2025 guide: low-mid single digit net sales growth (Q4 2024 +15.7% YoY)
   - 2026+ potential for double-digit growth with new acquisitions
   - CMS MUC payment rule provides stable pricing, ASP-based payment could accelerate growth

2. **Competitive Dynamics**: 
   - 90%+ hospital contracts ensure market leadership
   - Pylarify's F-18 isotope advantage vs competitors' Ga-68
   - Q4 2024 volume growth +2% qoq despite price increase

3. **Pipeline Progress**: 
   - MK-6240 Tau tracer NDA submission in 2025
   - NAV-4694 Beta Amyloid tracer NDA in 2026
   - Life Molecular Imaging adds Neuraceq Alzheimer's franchise
   - Evergreen's OCTEVY PET diagnostic pairs with PNT2003 radiotherapeutic

4. **Financial Guidance 2025**: 
   - Revenue: $1.545-1.61 billion (+1-5% YoY)
   - Adjusted EPS: $7-7.20 (+3.5-6.5% YoY)
   - R&D investment up 100-150bps as % of revenue
   - Free cash flow: $550-600 million


Actual											0.36	0.1	0.04	0.07	0.05	0.11	0.08	0.25	0.97	0.89	0.99	1.37	1.47	1.54	1.47	1.75	1.69	1.8	1.7	1.59	1.53	1.57	1.27	1.67
Forecast											0.2905	0.0631	-0.0581	0.0119	-0.01	0.0494	0.0633	0.1667	0.46	0.7029	0.8308	0.9611	1.2904	1.3096	1.3231	1.431	1.544	1.8296	1.5564	1.5432	1.6567	1.6754	1.2601	1.1995
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+23.92%	+58.48%	+168.85%	+488.24%	+600.00%	+122.67%	+26.38%	+49.97%	+110.87%	+26.62%	+19.16%	+42.55%	+13.92%	+17.59%	+11.10%	+22.29%	+9.46%	-1.62%	+9.23%	+3.03%	-7.65%	-6.29%	+0.79%	+39.22%

LNTH

LNTH fundamentals

LNTH Q4 2025 Earnings

Earnings Call

You can ask Aime

LNTH

LNTH fundamentals

LNTH Q4 2025 Earnings

Earnings Call

LNTH Earnings Call Summary for Q4/20258:00 AM on Feb 26, 2026

LNTH Earnings Call Summary for Q3/20258:00 AM on Nov 6, 2025

LNTH Earnings Call Summary for Q2/20258:00 AM on Aug 6, 2025

LNTH Earnings Call Summary for Q1/20258:00 AM on May 7, 2025

LNTH Earnings Call Summary for Q4/20248:00 AM on Feb 26, 2025

You can ask Aime